International Journal of Hematology

DOI: 10.1007/s12185-017-2278-1 Pages: 573-580

Costs of hematopoietic stem cell transplantation in a developing country

1. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Hematology and Oncology Department

2. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Current Accounts Department

Correspondence to:
Eucario Leon-Rodriguez
Tel: +52 55 54870900



Costs of HSCT in the United States have been widely reported, but complete information on costs in developing countries is lacking. We performed an analysis designed to assess the real, detailed costs of HSCT in Mexico. Using the database of the Current Accounts Department at our Institution, we performed a micro-costing based analysis of patients from 2010 through 2015 to obtain the overall cost of HSCT during the in-patient procedure and 2-month follow-up. One hundred five transplantations (57% autologous) were performed. The most frequent indications for transplantation were lymphomas (32%), followed by acute leukemias (22%). The most frequently used conditioning regimen was reduced BUCY 2 (38%), followed by BEAM (28%). Among post-transplant complications, acute graft-versus-host-disease was not associated with higher costs (p = 0.8). The median costs (in-patient and 2-month outpatient follow-up) for auto and allo-HSCT were 12,155 and 18,260 USD, respectively. Advances in HSCT technology have improved outcomes and increased the availability of this technique; however, this procedure can also significantly influence the socioeconomic wellbeing of patients, especially in developing countries. Our study highlights the feasibility of performing HSCT in Mexico at lower costs than developed countries, while preserving quality of care.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge